Immunogenicity and Clinical Efficacy of 20-valent Pneumococcal Conjugate Vaccine (PCV20) in Lymphoma Survivors After Treatment With Anti-CD20 Therapy

Launched by M.D. ANDERSON CANCER CENTER · Sep 15, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a new pneumonia vaccine called PCV20 in patients who have survived B-cell lymphoma and received a specific treatment called anti-CD20 therapy. The goal is to see how well the vaccine works when given as a single dose compared to a boosted dose, which is an extra shot given later. Researchers want to find out how effective this vaccine is in helping lymphoma survivors build protection against pneumonia, a serious lung infection.

To be eligible for this trial, participants must be at least 18 years old, have a history of non-Hodgkin B-cell lymphoma that has been in remission for at least one year, and have previously received anti-CD20 therapy. Patients who have had certain types of cell therapy or received any pneumonia vaccines in the past five years are not eligible. Those who join the study will receive the vaccine and will need to attend follow-up appointments at MD Anderson for monitoring. This trial is an important step in understanding how to better protect lymphoma survivors from pneumonia.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients who have a history of non-Hodgkin B-cell lymphoma and whose disease has been in remission for at least 1 year.
• • 2. Patients who received any anti-CD20 therapy at any time during their treatment for B-cell lymphoma.
• • 3. Patients who are at least 18 years of age.
• • 4. Patients who can provide consent; no legal authorized representative will be able to provide consent on a patient's behalf.
• Exclusion Criteria:
• • 1. Patients who have received cellular therapy, including chimeric antigen receptor T-cell therapy or any type of hematopoietic cell transplantation.
• • 2. Patients who have received PCV or pneumococcal polysaccharide vaccine within 5 years of screening for enrollment.
• • 3. Patients who are unable to attend follow-up appointments at designated times at MD Anderson.
• • 4. Any vulnerable population patient ((children, pregnant women, cognitively impaired adults, or prisoners)